knowledge -WSS

knowledge

author：explore 2025-10-03 00:37:46 - browse：9537

Rep. Larry Bucshon (R-Ind.) received a significant amount of campaign donations from the pharmaceutical industry in the second quarter of 2023. House Television via AP

WASHINGTON — The pharmaceutical industry has been flooding the campaign coffers of Rep. Larry Bucshon, a cardiothoracic surgeon and Republican from Indiana, according to a STAT analysis of this quarter’s filings.

CEOs of pharmaceutical giants, executives of the brand-drug lobby PhRMA, and companies’ political action committees all gave in higher-than-usual numbers to the rank-and-file House member last quarter. The total was nearly $56,000 between April 14 and June 30.

Bucshon is a member of the House Energy & Commerce Committee, which works on drug pricing issues, and the GOP Doctors Caucus, but he doesn’t hold leadership positions in either.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： ASCO eve: Let’s set the table for this year's meeting

WSS

Infant mortality in U.S. rose last year for first time in decades: CDC

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Key Senate panel to consider PBM, drug pricing reform package

Key Senate panel to consider PBM, drug pricing reform package

Live blog: Hearing on CRISPR

leisure time

knowledge

hotspot

Apple is now the first public company to be valued at $3 trillion

FDA poised to publish guidelines for clinical trial diversity

United colonoscopy coverage change 'may cost lives,' doctors say

After Sarepta trial failure, Duchenne families brace for more debate

Heart attack and stroke risk calculators need revising

All of Us, NIH's precision medicine initiative, gets a big boost

Walensky prepares to leave CDC — and Congress — behind

Live blog: Hearing on CRISPR

Dobbs anniversary: the lost opportunity of abortion as health care

Study finds gene variants tied to breast cancer risk in Black women

leisure time

FDA poised to publish guidelines for clinical trial diversity

After Sarepta trial failure, Duchenne families brace for more debate

Reports of telehealth's death have been greatly exaggerated

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Key Senate panel to consider PBM, drug pricing reform package

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

leisure time

focus

knowledge

Wikipedia